SCHEMBL691739

SCHEMBL691739

COC(=O)C1(Br)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1606853 0.95 NPSR1 (0.50)
SCHEMBL20740435 0.93 NPSR1 (0.48)
SCHEMBL1604408 0.93 NPSR1 (0.48)
SCHEMBL9008361 0.90
SCHEMBL24780851 0.79 CYP3A4 (0.41)
SCHEMBL20335470 0.79 NPSR1 (0.36)
SCHEMBL990527 0.77
SCHEMBL311023 0.75 SMN1; SMN2 (0.44)
SCHEMBL10835391 0.75 CYP4F2 (0.32)
SCHEMBL230256 0.74 NPSR1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909077-A 2- (1-bromocyclobutyl) pyridine and synthesis method thereof 南通大学 2020-11-10 CN claimed
CN-115960077-B Preparation method of apamide 山东新时代药业有限公司 2025-11-07 CN disclosed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2025067298-A1 COMPOUND AS GLUTAMINE CYCLASE INHIBITOR 先声药业有限公司 2025-04-03 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
CN-114573485-B Method for synthesizing alkynyl alkyl sulfide 华南理工大学 2023-11-10 CN disclosed
CN-115960077-A Preparation method of apaluamide 山东新时代药业有限公司 2023-04-14 CN disclosed
CN-115960077-A Preparation method of apaluamide 山东新时代药业有限公司 2023-04-14 CN disclosed
CN-114573485-A Method for synthesizing alkynyl alkyl thioether 华南理工大学 2022-06-03 CN disclosed
EP-2235017-B1 SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS HOFFMANN LA ROCHE (CH) 2011-09-14 EP disclosed
CN-101903388-A Spiroindolinone derivatives as anticancer agents HOFFMANN LA ROCHE 2010-12-01 CN disclosed
WO-2010121995-A1 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100273819-A1 3,3'-Spiroindolinone Derivatives CHEN LI 2010-10-28 US disclosed
EP-2235017-A1 SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. Hoffmann-La Roche AG (CH) 2010-10-06 EP disclosed
US-7776875-B2 such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents HOFFMAN-LA ROCHE INC. (US) 2010-08-17 US disclosed
WO-2009080488-A1 SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed
US-20090163512-A1 such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents CHEN LI 2009-06-25 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed